ARRY vs OKUR
ARRY: Array Technologies manufactures solar tracking systems that maximize photovoltaic panel efficiency for utility-scale and commercial renewable energy projects globally. OKUR: OnKure Therapeutics is a clinical-stage biotech developing precision small molecule drugs that selectively target mutated proteins to treat cancer and vascular anomalies while sparing healthy tissue.
Side-by-side fundamentals
| Metric | ARRY | OKUR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.82 | $4.32 | |
| Market cap as of 2026-07-23 | $895M | $175M | |
| PEG as of 2026-07-23 | 0.95 | n/a | |
| Net margin as of 2026-07-23 | -5.6% | n/a | |
| Gross margin as of 2026-07-23 | +26.1% | n/a | |
| Operating margin as of 2026-07-23 | -2.9% | n/a | |
| ROE as of 2026-07-23 | -20.6% | -61.0% | ARRY higher |
| ROA as of 2026-07-23 | -4.4% | -56.0% | ARRY higher |
| Debt / equity as of 2026-07-23 | 2.65 | 0.00 | OKUR lower |
| Revenue growth (YoY) as of 2026-07-23 | +13.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -7.8% | n/a | |
| Beta as of 2026-07-23 | 1.82 | 0.23 | |
| 1-year return as of 2026-07-22 close | -17.6% | +79.7% | OKUR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.